EcoR1 Capital’s Vaxcyte PCVX Stock Holding History

EcoR1 Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-450,000	Closed	-$20.8M	–	39
2025 Q4	$20.8M	Buy	+450,000	New	+$20.1M	0.94%	18
2024 Q4	–	Sell	-352,464	Closed	-$40.3M	–	69
2024 Q3	$40.3M	Buy	352,464 +52,464	+17%	+$4.73M	1.38%	19
2024 Q2	$22.7M	Hold	300,000	–	–	0.69%	30
2024 Q1	$20.5M	Buy	+300,000	New	+$20.8M	0.52%	35
2022 Q2	–	Sell	-1,304,741	Closed	-$31.5M	–	89
2022 Q1	$31.5M	Buy	1,304,741 +1,283,941	+6,173%	+$28.1M	0.99%	25
2021 Q4	$495K	Buy	+20,800	New	+$484K	0.02%	73

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital's PCVX Position: Q1 2026 in Review

EcoR1 Capital sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 450,000 shares — an estimated $20.8M sold.

EcoR1 Capital first reported a position in PCVX in Q4 2021 and held it in 6 quarters. The position peaked at $40.3M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

EcoR1 Capital reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
EcoR1 Capital sold 450,000 Vaxcyte shares in Q1 2026, an estimated $20.8M.
EcoR1 Capital first reported a position in Vaxcyte in Q4 2021 and held it in 6 quarters.
EcoR1 Capital's Vaxcyte position peaked at $40.3M in Q3 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.